Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) Shares Outstanding (Weighted Average): 2015-2024

Historic Shares Outstanding (Weighted Average) for Voyager Therapeutics (VYGR) over the last 10 years, with Dec 2024 value amounting to $54.6 million.

  • Voyager Therapeutics' Shares Outstanding (Weighted Average) rose 1.72% to $55.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.5 million, marking a year-over-year increase of 1.72%. This contributed to the annual value of $54.6 million for FY2024, which is 24.16% up from last year.
  • As of FY2024, Voyager Therapeutics' Shares Outstanding (Weighted Average) stood at $54.6 million, which was up 24.16% from $44.0 million recorded in FY2023.
  • In the past 5 years, Voyager Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $54.6 million in FY2024 and a low of $37.5 million during FY2020.
  • In the last 3 years, Voyager Therapeutics' Shares Outstanding (Weighted Average) had a median value of $44.0 million in 2023 and averaged $45.7 million.
  • Data for Voyager Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY rose of 24.16% (in 2024) over the last 5 years.
  • Voyager Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $37.5 million in 2020, then grew by 1.31% to $38.0 million in 2021, then rose by 1.71% to $38.6 million in 2022, then grew by 13.96% to $44.0 million in 2023, then grew by 24.16% to $54.6 million in 2024.